Program
Pan-KRAS Inhibitor BLU-924
In Sanofi’s pipeline, Pan KRAS inhibitor
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Sanofi.
Furthest: phase 2, since Jun 1, 20261 company-led study, 1 open or runningNext primary completion: Sep 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 11 open or running | phase 2since Jun 1, 2026 | Jun 1, 2026 | Sep 2029phase 2 · NCT07629960 |
- Named in Sanofi’s own pipeline as
SAR449336
, phase 1, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 1, 2026First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07629960 · 265 planned · United States, Spain
Ahead
- Sep 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07629960
TargetBeta
“Pan KRAS inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable inhibitor of various KRAS mutations, with potential antineoplastic activity. Upon oral administration, pan-KRAS inhibitor BLU-924 targets, binds to and inhibits various forms of KRAS mutations, thereby inhibiting KRAS-dependent signaling. This inhibits the proliferation of …”NCIt, read by Claude
“An orally bioavailable inhibitor of various KRAS mutations, ”NCIt, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07629960Carcinoma, Non-Small-Cell Lung · United States, Spain | 2 | Recruiting | Sep 2029 | 265 |
How it is read
Names in the registry
- “BLU-924”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.